These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 18402717)

  • 21. Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety.
    Martinez-de-la-Casa JM; Castillo A; Garcia-Feijoo J; Mendez-Hernandez C; Fernandez-Vidal A; Garcia-Sanchez J
    Curr Med Res Opin; 2004 Sep; 20(9):1333-9. PubMed ID: 15383180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial.
    Fechtner RD; Myers JS; Hubatsch DA; Budenz DL; DuBiner HB
    Eye (Lond); 2016 Oct; 30(10):1343-1350. PubMed ID: 27367743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost.
    Cheng JW; Li Y; Wei RL
    Ophthalmic Res; 2009; 42(2):99-105. PubMed ID: 19546601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
    Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
    J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
    Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma.
    Tsukamoto H; Noma H; Matsuyama S; Ikeda H; Mishima HK
    J Ocul Pharmacol Ther; 2005 Apr; 21(2):170-3. PubMed ID: 15857284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension.
    Mishra A; Agrawal M; Tripathi A; Bhirud A; Kumar LCR; Vinod K BB
    J Ocul Pharmacol Ther; 2024 May; 40(4):240-245. PubMed ID: 38598266
    [No Abstract]   [Full Text] [Related]  

  • 28. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
    Katz LJ
    J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
    Simmons ST;
    Clin Ther; 2001 Apr; 23(4):604-19. PubMed ID: 11354394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
    Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
    Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes.
    Mundorf T; Wilcox KA; Ousler GW; Welch D; Abelson MB
    Adv Ther; 2003; 20(6):329-36. PubMed ID: 15058750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study.
    Kampik A; Arias-Puente A; O'Brart DP; Vuori ML;
    J Glaucoma; 2002 Apr; 11(2):90-6. PubMed ID: 11912355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asymmetry of 24-hour intraocular pressure reduction by topical ocular hypotensive medications in fellow eyes.
    Liu JH; Realini T; Weinreb RN
    Ophthalmology; 2011 Oct; 118(10):1995-2000. PubMed ID: 21676464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes.
    Wang RF; Serle JB; Gagliuso DJ; Podos SM
    J Glaucoma; 2000 Dec; 9(6):458-62. PubMed ID: 11131752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study.
    Jin SW; Lee SM
    J Ocul Pharmacol Ther; 2018 Apr; 34(3):274-279. PubMed ID: 29297751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The intraocular pressure reducing effect of brinzolamide as adjunctive therapy to latanoprost.
    Li Yim JF; Montgomery DM
    Curr Med Res Opin; 2011 Aug; 27(8):1499-502. PubMed ID: 21651425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.
    Lusthaus JA; Goldberg I
    Expert Opin Drug Saf; 2017 Sep; 16(9):1071-1078. PubMed ID: 28656780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy.
    Goldberg I; Crowston JG; Jasek MC; Stewart JA; Stewart WC;
    J Glaucoma; 2012 Jan; 21(1):55-9. PubMed ID: 21048504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe.
    García-Sánchez J; Rouland JF; Spiegel D; Pajic B; Cunliffe I; Traverso C; Landry J
    Br J Ophthalmol; 2004 Jul; 88(7):877-83. PubMed ID: 15205229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.